Literature DB >> 11795261

The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity.

S Konstantinides1, K Schafer, D J Loskutoff.   

Abstract

Human obesity is associated with leptin resistance, elevated leptin levels in the circulation, and increased risk of arterial and venous thrombotic disease. Our studies suggest that elevated leptin levels may directly promote arterial thrombosis in vivo. We found that leptin-deficient ob/ob mice had prolonged times to thrombosis after arterial injury with ferric chloride and that exogenously administered leptin corrected their phenotype in a dose-dependent manner. These effects appear to result from a direct, receptor-mediated effect of leptin on platelets, because leptin stimulated the aggregation of murine (wild-type and ob/ob) and human platelets, but it had no effect on platelets from leptin receptor-deficient db/db mice. Moreover, db/db mice had an attenuated thrombotic response to ferric chloride injury (indistinguishable from that of the ob/ob mice), which was unaffected by exogenous leptin. Our results raise the possibility that elevated plasma levels of leptin may contribute to the risk of atherothrombotic complications in human obesity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11795261

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

Review 1.  Has the Time Come to Be More Aggressive With Bariatric Surgery in Obese Patients With Chronic Systolic Heart Failure?

Authors:  Amanda R Vest
Journal:  Curr Heart Fail Rep       Date:  2018-06

2.  Novel locus for fibrinogen in 3' region of LEPR gene in island population of Vis (Croatia).

Authors:  Željka Tomas; Matea Zajc Petranović; Tatjana Škarić-Jurić; Ana Barešić; Marijana Peričić Salihović; Nina Smolej Narančić
Journal:  J Hum Genet       Date:  2014-10-09       Impact factor: 3.172

Review 3.  The Head-to-Toe Hormone: Leptin as an Extensive Modulator of Physiologic Systems.

Authors:  Monica Misch; Prasanth Puthanveetil
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

Review 4.  Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells.

Authors:  Giovanni Anfossi; Isabella Russo; Gabriella Doronzo; Alice Pomero; Mariella Trovati
Journal:  Mediators Inflamm       Date:  2010-06-28       Impact factor: 4.711

Review 5.  Inflammation, oxidative stress and renin angiotensin system in atherosclerosis.

Authors:  Kazim Husain; Wilfredo Hernandez; Rais A Ansari; Leon Ferder
Journal:  World J Biol Chem       Date:  2015-08-26

Review 6.  Coagulation and fibrinolysis abnormalities in obesity.

Authors:  G De Pergola; N Pannacciulli
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

7.  Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines.

Authors:  Manfredi Tesauro; Maria Paola Canale; Giuseppe Rodia; Nicola Di Daniele; Davide Lauro; Angelo Scuteri; Carmine Cardillo
Journal:  Cardiol Res Pract       Date:  2011-03-07       Impact factor: 1.866

8.  Neuroprotection by leptin in a rat model of permanent cerebral ischemia: effects on STAT3 phosphorylation in discrete cells of the brain.

Authors:  D Amantea; C Tassorelli; R Russo; F Petrelli; L A Morrone; G Bagetta; M T Corasaniti
Journal:  Cell Death Dis       Date:  2011-12-08       Impact factor: 8.469

Review 9.  Depression and Cardiovascular Disease: The Viewpoint of Platelets.

Authors:  Patrizia Amadio; Marta Zarà; Leonardo Sandrini; Alessandro Ieraci; Silvia Stella Barbieri
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

Review 10.  Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.

Authors:  Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.